Eli Lilly's Obesity Drug Shows Modest Growth as Competition with Novo Nordisk Intensifies
Eli Lilly's obesity drug, Foundayo, saw a modest increase in prescriptions during its second week, with 3,707 prescriptions compared to 1,390 in its first week. This growth is significantly lower than Novo Nordisk's Wegovy, which achieved 18,410 prescriptions in its second week. The slower uptake of Foundayo has led to negative market reactions, with Lilly's shares falling nearly 4%.
Topics: drug launches market competition obesity drugs pharmaceuticals stock performance